Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.25
CRME's Cash to Debt is ranked lower than
69% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CRME: 2.25 )
Ranked among companies with meaningful Cash to Debt only.
CRME' s Cash to Debt Range Over the Past 10 Years
Min: 0.64  Med: 84.26 Max: No Debt
Current: 2.25
Equity to Asset 0.48
CRME's Equity to Asset is ranked lower than
71% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRME: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
CRME' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.79 Max: 0.99
Current: 0.48
-0.01
0.99
F-Score: 3
Z-Score: -5.80
M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -92.86
CRME's Operating margin (%) is ranked lower than
53% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CRME: -92.86 )
Ranked among companies with meaningful Operating margin (%) only.
CRME' s Operating margin (%) Range Over the Past 10 Years
Min: -4312.67  Med: -373.14 Max: 55.51
Current: -92.86
-4312.67
55.51
Net-margin (%) -101.89
CRME's Net-margin (%) is ranked lower than
55% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CRME: -101.89 )
Ranked among companies with meaningful Net-margin (%) only.
CRME' s Net-margin (%) Range Over the Past 10 Years
Min: -3763.2  Med: -253.02 Max: 105.81
Current: -101.89
-3763.2
105.81
ROE (%) -130.87
CRME's ROE (%) is ranked lower than
86% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CRME: -130.87 )
Ranked among companies with meaningful ROE (%) only.
CRME' s ROE (%) Range Over the Past 10 Years
Min: -127.25  Med: -81.00 Max: 93.76
Current: -130.87
-127.25
93.76
ROA (%) -49.37
CRME's ROA (%) is ranked lower than
68% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CRME: -49.37 )
Ranked among companies with meaningful ROA (%) only.
CRME' s ROA (%) Range Over the Past 10 Years
Min: -101.59  Med: -40.11 Max: 46.4
Current: -49.37
-101.59
46.4
ROC (Joel Greenblatt) (%) -533.06
CRME's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CRME: -533.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRME' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1658.04  Med: -1043.11 Max: 1546.19
Current: -533.06
-1658.04
1546.19
Revenue Growth (3Y)(%) 154.00
CRME's Revenue Growth (3Y)(%) is ranked higher than
98% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CRME: 154.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRME' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.8  Med: 43.00 Max: 205.2
Current: 154
-75.8
205.2
EBITDA Growth (3Y)(%) -20.60
CRME's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CRME: -20.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRME' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.5  Med: 2.70 Max: 27
Current: -20.6
-47.5
27
EPS Growth (3Y)(%) -17.90
CRME's EPS Growth (3Y)(%) is ranked lower than
67% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CRME: -17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRME' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.8  Med: -0.25 Max: 24.2
Current: -17.9
-48.8
24.2
» CRME's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CRME Guru Trades in Q1 2015

Jim Simons 97,113 sh (+25.94%)
» More
Q2 2015

CRME Guru Trades in Q2 2015

Jim Simons 91,647 sh (-5.63%)
» More
Q3 2015

CRME Guru Trades in Q3 2015

Jim Simons 66,613 sh (-27.32%)
» More
Q4 2015

CRME Guru Trades in Q4 2015

Jim Simons 62,213 sh (-6.61%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 312.50
CRME's Forward P/E is ranked lower than
98% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. CRME: 312.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.78
CRME's P/B is ranked lower than
65% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CRME: 3.78 )
Ranked among companies with meaningful P/B only.
CRME' s P/B Range Over the Past 10 Years
Min: 1.02  Med: 6.81 Max: 29.65
Current: 3.78
1.02
29.65
P/S 3.65
CRME's P/S is ranked higher than
76% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. CRME: 3.65 )
Ranked among companies with meaningful P/S only.
CRME' s P/S Range Over the Past 10 Years
Min: 3.24  Med: 22.94 Max: 305.91
Current: 3.65
3.24
305.91
Current Ratio 2.32
CRME's Current Ratio is ranked lower than
71% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CRME: 2.32 )
Ranked among companies with meaningful Current Ratio only.
CRME' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 7.53 Max: 97.75
Current: 2.32
1.14
97.75
Quick Ratio 2.02
CRME's Quick Ratio is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CRME: 2.02 )
Ranked among companies with meaningful Quick Ratio only.
CRME' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 7.53 Max: 97.75
Current: 2.02
1.07
97.75
Days Inventory 255.97
CRME's Days Inventory is ranked lower than
79% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. CRME: 255.97 )
Ranked among companies with meaningful Days Inventory only.
CRME' s Days Inventory Range Over the Past 10 Years
Min: 207.9  Med: 747.09 Max: 1286.27
Current: 255.97
207.9
1286.27
Days Sales Outstanding 91.73
CRME's Days Sales Outstanding is ranked lower than
66% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CRME: 91.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRME' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.04  Med: 148.34 Max: 540.02
Current: 91.73
4.04
540.02
Days Payable 224.40
CRME's Days Payable is ranked higher than
85% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. CRME: 224.40 )
Ranked among companies with meaningful Days Payable only.
CRME' s Days Payable Range Over the Past 10 Years
Min: 199.26  Med: 1214.72 Max: 2230.17
Current: 224.4
199.26
2230.17

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.40
CRME's Price/Net Current Asset Value is ranked lower than
66% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. CRME: 9.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRME' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.11  Med: 7.43 Max: 279.5
Current: 9.4
1.11
279.5
Price/Tangible Book 8.43
CRME's Price/Tangible Book is ranked lower than
73% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. CRME: 8.43 )
Ranked among companies with meaningful Price/Tangible Book only.
CRME' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 6.99 Max: 213.6
Current: 8.43
1.11
213.6
Price/Median PS Value 0.17
CRME's Price/Median PS Value is ranked higher than
93% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. CRME: 0.17 )
Ranked among companies with meaningful Price/Median PS Value only.
CRME' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.71 Max: 78.26
Current: 0.17
0.18
78.26
Earnings Yield (Greenblatt) (%) -23.04
CRME's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CRME: -23.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRME' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -23.04  Med: 5.80 Max: 669494.2
Current: -23.04
-23.04
669494.2

More Statistics

Revenue(Mil) $23
EPS $ -1.36
Beta1.48
Short Percentage of Float1.52%
52-Week Range $4.71 - 10.44
Shares Outstanding(Mil)20.15

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 35 47 59 71
EPS($) -1.54 -0.74 -0.45 -0.25
EPS without NRI($) -1.54 -0.74 -0.45 -0.25

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:COM.Canada, CKO1.Germany,
Cardiome Pharma Corp was incorporated on December 12, 1986. The Company is a specialty pharmaceutical company engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It currently has two marketed, in-hospital, cardiology products, BRINAVESS, for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adultsand and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in Acute Coronary Syndrome patients. Both of its products are commercially available in numerous markets outside of the United States. BRINAVESS was approved in September 2010 and has been launched in the European Union, Iceland and Norway.
» More Articles for CRME

Headlines

Articles On GuruFocus.com
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

More From Other Websites
Cardiome To Present At The 5th Annual Leerink Partners Global Healthcare Conference Feb 10 2016
Cardiome To Present At The 5th Annual Leerink Partners Global Healthcare Conference Feb 10 2016
Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA Jan 27 2016
Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA Jan 27 2016
Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA Jan 27 2016
Cardiome Announces the Launch of ESMOCARD LYO in Belgium Jan 21 2016
Cardiome Announces the Launch of ESMOCARD LYO in Belgium Jan 21 2016
Cardiome Announces the Launch of ESMOCARD LYO in Belgium Jan 21 2016
Cardiome announces filing of marketing authorization application for intravenous vernakalant in the... Jan 13 2016
Cardiome announces filing of marketing authorization application for intravenous vernakalant in the... Jan 13 2016
Cardiome announces filing of marketing authorization application for intravenous vernakalant in the... Jan 13 2016
Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Jan 12 2016
Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Jan 12 2016
Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Jan 12 2016
Cardiome/SteadyMed's PAH Drug Approved for Review in EU Jan 07 2016
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK